Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Females must be post-menopausal for more than 2 years or surgically sterile or practicing specific forms of birth control~2. Chronic hepatitis C, genotype 1-infection (HCV RNA level greater than 1,000 IU/mL at screening)~3. HCV genotype 1 infection per screening laboratory result~Exclusion Criteria:~1. Use of contraindicated medications within 2 weeks of dosing~2. Abnormal laboratory tests~3. Positive hepatitis B surface antigen and anti-Human Immunodeficiency Virus Antibody~4. History of solid organ transplant, clinical evidence of Child-Pugh B or C classification or clinical history of liver decompensation~5. Presence of hepatocellular carcinoma at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV) (Type: EXPERIMENTAL): Participants with HCV GT1b without cirrhosis received the 3-DAA (ABT-450/ritonavir/ABT-267 and ABT-333) regimen: two 75 mg ABT-450/50 mg ritonavir/12.5 mg ABT-267 tablets taken orally every morning (QD) and one ABT-333 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis and those with HCV GT1b with cirrhosis received the 3-DAA regimen and weight-based ribavirin (RBV; 1000 to 1200 mg divided twice daily per local label) for 12 weeks. Participants with HCV GT1a with cirrhosis received the 3-DAA regimen and weight-based RBV per local label for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).